Bonnie A. Avery, Ph.D.


Bonnie A. Avery, Ph.D.

Clinical Professor of Pharmaceutics

Director, UF Translational Drug Development Core Lab

College of Pharmacy


Office: Medical Science Building, P1-27

1345 Center Drive

PO Box 100494

Gainesville, FL 32610

Office (352) 294-8690

Fax (352) 275-7705

Research Summary: Dr. Avery’s research focuses on in vitro and in vivo pre-clinical pharmacokinetics of novel compounds.



Institution, Degree and Year

The University of North Dakota (Ph.D.), 1994

Grand Forks, North Dakato 58202

Department of Chemistry (Analytical Chemistry)

Dissertation Advisor: Dr. David C. Tilotta; Dissertation Title: “Analytical Applications of Near Infrared Molecular Emission Spectroscopy”

Minot State University (B.A.), 1990

Minot, North Dakota 58707 (Chemistry)

Minot State University (B.S.), 1982

Minot, North Dakota 58707 (Medical Technology)

Current Research

Dr. Bonnie Avery is a broadly trained scientist whose research focuses in the areas of physical pharmaceutics and pre-clinical pharmacokinetics.  For over 20 years the majority of her research has centered on novel method development and validation for identification and quantification of active compounds.  Within the past 15 years she has extended the boundaries of her research to include pre-clinical pharmacokinetics. She has developed her skills in areas including but not limited to: basic in vivo pharmacokinetic studies in rats; in vitro liver microsomal stability; in situ liver perfusion assay; protein binding, determination of blood brain ratios, P-gp studies, and drug tissue accumulation studies.  In collaboration with groups in medicinal chemistry and natural product drug discovery, she has successfully managed pharmacokinetic research on over 30 novel compounds including antimalarials, anticancer compounds, Neuropeptide FF and sigma receptor ligand/probes, paciltaxel pro-drugs, synthetic thiazolidinedione, CoQ10, and a novel epothilone D analogs.   Dr. Avery serves as the laboratory director of the UF Translational Drug Development Core.

Recent publications

  1. Shen, B.; Park, J.H.; Hjornevik, T.; Cipriano, P.W.; Yoon, D.; Gulaka, P.K.; Holly, D.; Behera, D.; Avery, B.A.; Gambhir, S.S.; McCurdy, C.R.; Biswal, S.; Chin, F.T. Radiosynthesis and First-in-Human PET/MRI Evaluation with Clinical-Grade [18F]FTC-146.  Molecular Imaging and Biology, 2017, Web Published March 9, 2017.  DOI: 10.1007/s11307-017-1064-z PMID: 28280965
  2. Avery, B.A.; Vuppala, P.K.; Jamalapuram, S.; Sharma, A.; Mesangeau, C.; Chin, F.T.; McCurdy, C.R.  Quantification of Highly Selective Sigma-1 Receptor Antagonist CM304 using Liquid Chromatography Tandem Mass Spectrometry and its application to a Pre-clinical Pharmacokinetic Study.  Drug Testing and Analysis, 2016, Web Published December 30, 2016. DOI: 10.1002/dta.2156 PMID: 28039926
  3. Lydecker, A.G.; Sharma, A.; McCurdy, C.R.; Avery, B.A.; Babu, K.M.; Boyer, E.W.  Suspected Adulteration of Commercial Kratom Products with 7-Hydroxymitragynine.  Journal of Medical Toxicology, 2016, 12, 341-349.  Web Published October 17, 2016.  DOI: 10.1007/s13181-016-0588-y PMID: 27752985
  4. James, M.L.; Shen, B.; Nielsen, C.H.; Behera, D.; Buckmaster, C.L.; Mesangeau, C.; Zavaleta, C.; Vuppala, P.K.; Jamalapuram, S.; Avery, B.A.; Lyons, D.M.; McCurdy, C.R.; Biswal, S.; Gambhir, S.S.; Chin, F.T.  Evaluation of Sigma-1 Receptor Radioligand [18F]FTC-146 in Rats and Squirrel Monkeys using Positron Emission Tomography.  Journal of Nuclear Medicine, 2014, 55, 147-153.  Web Published December 12, 2013.  DOI:  10.2967/jnumed.113.121.0261 PMID: 24337599
  5. Vuppala, P.K.; Jamalapuram, S.; Furr, E.B.; McCurdy, C.R.; Avery, B.A. Development and validation of a UPLC-MS/MS method for the determination of 7-hydroxymitragynine, a m-opioid agonist, in rat plasma and its application to a pharmacokinetic study.  Biomedical Chromatography, 2013, 12, 1726-1732.  Web Published July 24, 2013.  DOI:  10.1002/bmc.2986 PMID: 23893615